- $2.03bn
- $2.22bn
- $1.25bn
- 79
- 65
- 46
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.19 | ||
| PEG Ratio (f) | 0.32 | ||
| EPS Growth (f) | 46.46% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.53 | ||
| Price to Tang. Book | 6.08 | ||
| Price to Free Cashflow | 14.9 | ||
| Price to Sales | 1.62 | ||
| EV to EBITDA | 15.87 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.63% | ||
| Return on Equity | 4.87% | ||
| Operating Margin | 7.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 934.24 | 1,035.37 | 1,021.8 | 1,153.55 | 1,253.44 | 1,300.24 | 1,371.5 | 2.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +486.68 | +9.54 | +77.65 | +8.77 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
Directors
- Daniel Moore CHM (60)
- Damien McDonald CEO (56)
- Alex Shvartsburg CFO (51)
- Trui Hebbelinck CHO (49)
- Keyna Skeffington SVP (59)
- Marco Dolci OTH (59)
- Francesco Bianchi IND (64)
- William Kozy IND (70)
- Alfred Novak IND (73)
- Sharon O'Kane IND (53)
- Arthur Rosenthal IND (74)
- Andrea Saia IND (63)
- Todd Schermerhorn IND (60)
- Stacy Seng IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 20th, 2015
- Public Since
- October 19th, 2015
- No. of Shareholders
- 20
- No. of Employees
- 2,900
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 54,351,765
- Address
- 20 Eastbourne Terrace, LONDON, W2 6LG
- Web
- https://www.livanova.com/
- Phone
- +44 2033250662
- Contact
- Briana Gotlin
- Auditors
- PricewaterhouseCoopers LLP
Latest News for LIVN
Upcoming Events for LIVN
Q1 2025 LivaNova PLC Earnings Release
Q1 2025 LivaNova PLC Earnings Call
LivaNova PLC Annual Shareholders Meeting
Q2 2025 LivaNova PLC Earnings Release
Similar to LIVN
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 21:46 UTC, shares in Livanova are trading at $37.26. This share price information is delayed by 15 minutes.
Shares in Livanova last closed at $37.26 and the price had moved by -32.38% over the past 365 days. In terms of relative price strength the Livanova share price has underperformed the S&P500 Index by -37.58% over the past year.
The overall consensus recommendation for Livanova is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLivanova does not currently pay a dividend.
Livanova does not currently pay a dividend.
Livanova does not currently pay a dividend.
To buy shares in Livanova you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $37.26, shares in Livanova had a market capitalisation of $2.03bn.
Here are the trading details for Livanova:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LIVN
Based on an overall assessment of its quality, value and momentum Livanova is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Livanova is $60.67. That is 62.83% above the last closing price of $37.26.
Analysts covering Livanova currently have a consensus Earnings Per Share (EPS) forecast of $3.56 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Livanova. Over the past six months, its share price has underperformed the S&P500 Index by -25.9%.
As of the last closing price of $37.26, shares in Livanova were trading -21.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Livanova PE ratio based on its reported earnings over the past 12 months is 10.19. The shares last closed at $37.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Livanova's management team is headed by:
- Daniel Moore - CHM
- Damien McDonald - CEO
- Alex Shvartsburg - CFO
- Trui Hebbelinck - CHO
- Keyna Skeffington - SVP
- Marco Dolci - OTH
- Francesco Bianchi - IND
- William Kozy - IND
- Alfred Novak - IND
- Sharon O'Kane - IND
- Arthur Rosenthal - IND
- Andrea Saia - IND
- Todd Schermerhorn - IND
- Stacy Seng - IND